Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of HCP1903 (Rosuvastatin/Ezetimibe) in Healthy Subjects
NCT04762407Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Nov 2020
- Primary completion
- Feb 2021
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HCP1903 in hypercholesterolemia and dyslipidemia (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Plasma Concentration (Cmax) of Rosuvastatin at 72 hours, Area Under the Curve to the Last Quantifiable Concentration (AUClast) of Rosuvastatin at 72 hours and 2 more. Started Nov 2020; status: completed.
02
Drugs
HCP1903
03
Conditions
hypercholesterolemiadyslipidemia
Beyond the preview
Go deeper on NCT04762407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762407.